Respiratory disorders of the neonate.
Respiratory disorders remain a major cause of neonatal mortality and morbidity. This review focuses on clinical trials and diagnostic procedures in neonatal respiratory disorders reported from October 1991 to September 1992. It leaves out animal studies, artificial ventilation techniques, extracorporeal membrane oxygenation, and follow-up studies. Surfactant substitution comes of age and first side effects of this successful treatment are described. Infection with ureaplasma urealyticum seems to contribute to chronic lung disease. The latter can be effectively treated with dexamethasone. However, because of numerous and severe side effects, this treatment requires scrupulous risk-benefit evaluation in each case.
Obladen
M
M
Department of Neonatology, Children's Hospital, UniversiTätsklinikum Rudolf Virchow, Berlin, Germany.
Maier
R F
RF
D001997:Bronchopulmonary Dysplasia / Q000188:drug therapy / Q000503:physiopathology; D002986:Clinical Trials as Topic; D003907:Dexamethasone / Q000627:therapeutic use; D006801:Humans; D007231:Infant, Newborn; D008171:Lung Diseases / Q000175:diagnosis / Q000503:physiopathology / Q000628:therapy; D011663:Pulmonary Surfactants / Q000627:therapeutic use; D012120:Respiration Disorders / Q000175:diagnosis / Q000503:physiopathology / Q000628:therapy; D012127:Respiratory Distress Syndrome, Newborn / Q000503:physiopathology / Q000628:therapy; D016869:Ureaplasma Infections / Q000175:diagnosis / Q000628:therapy
D011663:Pulmonary Surfactants; D003907:Dexamethasone